Get the Stockscreener App
1.17
2.10%
-0.02
After Hours:
1.17
Heron Therapeutics Inc stock is traded at $1.17, with a volume of 1.37M.
It is down -2.10% in the last 24 hours and down -33.81% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.19
Open:
$1.19
24h Volume:
1.37M
Relative Volume:
0.77
Market Cap:
$180.48M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-1.00
EPS:
-1.17
Net Cash Flow:
$-9.61M
1W Performance:
-36.68%
1M Performance:
-33.81%
6M Performance:
-63.59%
1Y Performance:
+6.88%
1-Day Range:
$1.13
$1.215
1-Week Range:
$1.04
$1.53
52-Week Range:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| HRTX | 1.17 | 180.48M | 137.74M | -27.97M | -9.61M | -1.17 |
| VRTX | 467.12 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0% - MarketBeat
Northland Capmk Has Pessimistic View of HRTX Q4 Earnings - Defense World
Equities Analysts Set Expectations for HRTX Q4 Earnings - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Raised to Buy at StockNews.com - Defense World
Heron Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Has Lowered Expectations for Heron Therapeutics (NASDAQ:HRTX) Stock Price - MarketBeat
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge - Simply Wall St
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30% - Simply Wall St
Earnings call: Heron Therapeutics projects higher Q4 revenue By Investing.com - Investing.com UK
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance - TipRanks
Heron Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
Heron Therapeutics Inc (HRTX) Quarterly 10-Q Report - Quartz
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Heron Therapeutics reports Q3 EPS (3c), consensus (3c) - TipRanks
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - PR Newswire
Heron Therapeutics (HRTX) Set to Announce Earnings on Tuesday - Defense World
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Heron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock - Yahoo Finance UK
Heron Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - StockTitan
Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt - The Globe and Mail
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - Longview News-Journal
SG Americas Securities LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Antinauseants Market Insights, Forecast to 2031Heron - openPR
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat
Heron Therapeutics Inc (HRTX) deserves deeper analysis - US Post News
Investor’s Toolkit: Key Ratios for Assessing Heron Therapeutics Inc (HRTX)’s Performance - The Dwinnex
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Congress Park Capital LLC - MarketBeat
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - The Malaysian Reserve
Its Stock Has Paid Off Big Time For Heron Therapeutics Inc - SETE News
AQR Capital Management LLC Raises Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc Inc. (HRTX) Price Performance: The Role of Supply and Demand - The InvestChronicle
Can you now get a good deal on Heron Therapeutics Inc’s shares? - US Post News
Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Buying Buzz: Heron Therapeutics Inc [HRTX] EVP, Chief Development Officer Forbes William P purchases 25,000 shares of the company – Knox Daily - Knox Daily
HRTX’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St
Get in on Heron Therapeutics Inc’s (HRTX) buy-in window today! - SETE News
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Marshall Wace LLP - Defense World
Heron Therapeutics Inc’s results are impressive - US Post News
Marshall Wace LLP Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Market Momentum Report: Heron Therapeutics Inc (HRTX)’s Negative Close at 1.99 - The Dwinnex
Clearline Capital LP Sells 1,280,938 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):